Dong Kim - Mar 25, 2022 Form 4/A Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Mar 25, 2022
Transactions value $
$0
Form type
4/A
Date filed
2/12/2024, 05:43 PM
Date Of Original Report
Mar 29, 2022
Next filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Award $0 +20K $0.00 20K Mar 25, 2022 Ordinary Shares 20K $8.61 Direct F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One third of the shares underlying the stock option will vest on each of March 25, 2023, March 25, 2024 and March 25, 2025.
F2 This amendment corrects and restates the number of derivative securities acquired reported in the original Form 4 filed on March 29, 2022.
F3 This amendment corrects and restates the expiration date reported in the original Form 4 filed on March 29, 2022.
F4 This amendment corrects and restates the amount of securities underlying derivative security reported in the original Form 4 filed on March 29, 2022.
F5 This amendment corrects and restates the number of derivative securities beneficially owned following reported transaction reported in the original Form 4 filed on March 29, 2022.